Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2007 1
2008 4
2009 5
2010 8
2011 10
2012 12
2013 8
2014 7
2015 4
2016 9
2017 3
2018 9
2019 8
2020 9
2021 5
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.
Jakimovski D, Weinstock-Guttman B, Ramanathan M, Kolb C, Hojnacki D, Minagar A, Zivadinov R. Jakimovski D, et al. Among authors: hojnacki d. Expert Opin Biol Ther. 2017 Sep;17(9):1163-1172. doi: 10.1080/14712598.2017.1347632. Epub 2017 Jul 3. Expert Opin Biol Ther. 2017. PMID: 28658986 Review.
Use of natalizumab in multiple sclerosis: current perspectives.
Gandhi S, Jakimovski D, Ahmed R, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R. Gandhi S, et al. Among authors: hojnacki d. Expert Opin Biol Ther. 2016 Sep;16(9):1151-62. doi: 10.1080/14712598.2016.1213810. Epub 2016 Jul 27. Expert Opin Biol Ther. 2016. PMID: 27413840 Review.
Aging and Brain Atrophy in Multiple Sclerosis.
Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R. Ghione E, et al. Among authors: hojnacki d. J Neuroimaging. 2019 Jul;29(4):527-535. doi: 10.1111/jon.12625. Epub 2019 May 10. J Neuroimaging. 2019. PMID: 31074192
Detecting isolated cognitive relapses in persons with MS.
Morrow SA, Weinstock ZL, Mirmosayyeb O, Conway D, Fuchs T, Jaworski MG, Eckert S, Hojnacki DH, Dwyer MG, Zivadinov R, Weinstock-Guttman B, Benedict RHB. Morrow SA, et al. Among authors: hojnacki dh. Mult Scler. 2023 Dec;29(14):1786-1794. doi: 10.1177/13524585231201219. Epub 2023 Sep 30. Mult Scler. 2023. PMID: 37776097 Free PMC article.
High-mobility group box 1 in multiple sclerosis.
Sternberg Z, Sternberg D, Chichelli T, Drake A, Patel N, Kolb C, Chadha K, Yu J, Hojnacki D. Sternberg Z, et al. Among authors: hojnacki d. Immunol Res. 2016 Apr;64(2):385-91. doi: 10.1007/s12026-015-8673-x. Immunol Res. 2016. PMID: 26100980
Recovery of cognitive function after relapse in multiple sclerosis.
Benedict RH, Pol J, Yasin F, Hojnacki D, Kolb C, Eckert S, Tacca B, Drake A, Wojcik C, Morrow SA, Jakimovski D, Fuchs TA, Dwyer MG, Zivadinov R, Weinstock-Guttman B. Benedict RH, et al. Among authors: hojnacki d. Mult Scler. 2021 Jan;27(1):71-78. doi: 10.1177/1352458519898108. Epub 2020 Jan 23. Mult Scler. 2021. PMID: 31971066
Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
Satchidanand N, Drake A, Smerbeck A, Hojnacki D, Kolb C, Patrick K, Weinstock-Guttman B, Motl R, Benedict RH. Satchidanand N, et al. Among authors: hojnacki d. Mult Scler. 2020 Jan;26(1):91-98. doi: 10.1177/1352458518815795. Epub 2018 Dec 19. Mult Scler. 2020. PMID: 30566030 Clinical Trial.
91 results